Educational article

Lincosamides and inducible resistance

Clindamycin is a lincosamide acting on protein synthesis. Its spectrum includes selected Gram-positive bacteria and anaerobes, but not every member of those groups. Laboratory susceptibility is assessed separately from…

Overview

Clindamycin is a lincosamide acting on protein synthesis. Its spectrum includes selected Gram-positive bacteria and anaerobes, but not every member of those groups. Laboratory susceptibility is assessed separately from adverse-effect risk and clinical indications.

Biology and practical meaning

An apparently susceptible result can conceal inducible MLSB resistance. Standards specify additional checks for particular staphylococci and streptococci with the relevant profile. The D-test detects induction; it does not measure drug concentration or establish a clinical outcome.

Spectrum, exposure and AST

Spectrum describes the range of organisms an agent can act against; activity against a particular isolate is assessed separately. Access to the target, target changes, enzymes and efflux can alter activity. Agents in the same class are not completely interchangeable.

Pharmacokinetics describes distribution and elimination; pharmacodynamics links exposure to effect. Blood concentrations and exposure at the infection site can differ. A lower MIC number for a different antibiotic therefore does not establish superior clinical activity.

S, I and R are interpreted using a current standard for the organism–agent pair. Under EUCAST, I means susceptible with increased exposure. It does not mean resistant and does not independently specify a treatment regimen. Decisions also depend on the site, patient, contraindications, interactions and current guidance. This article explains mechanisms and terminology. The 2025 AWaRe classification concerns use policy, while the 2022 AWaRe book has subsequent updates; neither replaces an individual AST result.

Teaching example: from finding to conclusion

Teaching example: an isolate appears clindamycin-susceptible but erythromycin-resistant. In applicable organisms, this pattern raises an inducible-resistance question rather than completing the report.

Additional testing follows the accepted standard and may change the permissible clindamycin conclusion. The pattern alone does not prove a particular erm gene; efflux and other mechanisms differ. Guessing from two drug names cannot replace proper interpretation.

Sources

Read next

Educational material from AMR Atlas. Does not replace clinical guidance or laboratory procedures.

Open interactive reader